DPP4 acts as a receptor for a subset set of corona viruses cell entry, similar to ACE2 (27); however, just like for ACE inhibitors, there is currently insufficient scientific evidence to judge whether use of DPP4 inhibitors impacts adversely on type 2 diabetes patients with COVID-19 (28). Here, ACE is linked to COVID-19.